Answers are grounded in this paper and cite their sources.
To the Editor: Therapy with anti–tumor necrosis factor-α agents has changed the natural history of inflammatory bowel disease,1 reducing the risk of hospitalization and surgical intervention.2,3 However, anti–tumor necrosis factor-α agents have been associated with adverse events in clinical practice, and they have been rarely associated with cutaneous vasculitis. Establishing causality can be challenging because inflammatory bowel disease itself may also cause vasculitic manifestations.4,5 Here, we describe a case of cutaneous vasculitis in a patient receiving adalimumab therapy who was in clinical remission and presented healing of deep gut mucosa. A 28-year-old woman with a history of Crohn's disease refractory to conventional therapy started treatment with adalimumab in 2012. She had no history of cutaneous manifestations. After 24 months of adalimumab therapy, she reported raised purpuric lesions on her legs (Fig. 1A). She denied any accompanying manifestations such as joint pain or constitutional symptoms. These lesions appeared 2 months after the birth of her child. Laboratory tests results were normal, including C reactive protein, erythrocyte sedimentation rate, blood counts, urinalysis, and serum complement levels, antinuclear antibodies, anti-extractable nuclear antigens, rheumatoid factor, antineutrophil cytoplasmic antibodies, antiphospholipid antibodies, and cryoglobulins. A skin biopsy revealed features of leukocytoclastic vasculitis in postcapillary venules: dermis with superficial perivascular neutrophilic infiltrate, leukocytoclasis, edema, red blood cell extravasation, and fibrinoid necrosis of blood vessel walls (Fig. 1B). This finding was suggestive of cutaneous drug-induced vasculitis. Soon after the appearance of the purpuric lesions on thighs, legs, and ankles, prednisone was introduced at a dose of 60 mg qd (1 mg/kg), and adalimumab was discontinued. However, only a modest response was observed after 30 days of glucocorticoid therapy, and purpuric lesions at ankles and feet remained. We introduced colchicine 0.5 mg tid, after breastfeeding, and tapered prednisone to 40 mg per day. At this point, there were no laboratory abnormalities. Skin lesions gradually disappeared, and after 30 days of treatment, there were no visible active lesions. Prednisone was tapered progressively and maintained at minimal dose just to control Crohn's disease. Colchicine was also tapered and maintained at a dose of 0.5 mg/day. This case report illustrates cutaneous vasculitis as a potential association with anti–tumor necrosis factor-α therapy. In addition to stopping the suspected drug, colchicine may be helpful in patients refractory to high-dose glucocorticoids.
No takes yet. Share an insight, caveat, or question.
Cury et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: